MCID: OVR094
MIFTS: 44

Ovarian Epithelial Cancer

Categories: Rare diseases, Cancer diseases

Aliases & Classifications for Ovarian Epithelial Cancer

MalaCards integrated aliases for Ovarian Epithelial Cancer:

Name: Ovarian Epithelial Cancer 50 29
Epithelial Ovarian Cancer 50 69
Ovarian Epithelial Carcinoma 50
Ovarian Cancer, Epithelial 50
Eoc 50

Classifications:



Summaries for Ovarian Epithelial Cancer

MalaCards based summary : Ovarian Epithelial Cancer, also known as epithelial ovarian cancer, is related to ovarian cancer, somatic and brain ependymoma. An important gene associated with Ovarian Epithelial Cancer is MUC4 (Mucin 4, Cell Surface Associated), and among its related pathways/superpathways are Focal Adhesion and PI3K-Akt signaling pathway. The drugs Doxorubicin and Bevacizumab have been mentioned in the context of this disorder. Affiliated tissues include bone, lung and ovary, and related phenotypes are endocrine/exocrine gland and homeostasis/metabolism

Related Diseases for Ovarian Epithelial Cancer

Graphical network of the top 20 diseases related to Ovarian Epithelial Cancer:



Diseases related to Ovarian Epithelial Cancer

Symptoms & Phenotypes for Ovarian Epithelial Cancer

MGI Mouse Phenotypes related to Ovarian Epithelial Cancer:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.98 MAPK1 PHB AKT2 PTGS1 BIRC5 COL1A1
2 homeostasis/metabolism MP:0005376 9.95 COL1A1 PTGS2 MAPK1 PHB AKT2 BIRC5
3 mortality/aging MP:0010768 9.87 COL1A1 PTGS2 MAPK1 PHB AKT2 BIRC5
4 integument MP:0010771 9.85 MAPK1 PHB AKT2 PTGS1 COL1A1 PTGS2
5 muscle MP:0005369 9.65 PTGS2 MAPK1 AKT2 PTGS1 COL1A1
6 neoplasm MP:0002006 9.55 MAPK1 AKT2 PTGS1 COL1A1 PTGS2
7 reproductive system MP:0005389 9.43 MAPK1 PHB AKT2 PTGS1 COL1A1 PTGS2
8 respiratory system MP:0005388 9.02 MAPK1 AKT2 PTGS1 COL1A1 PTGS2

Drugs & Therapeutics for Ovarian Epithelial Cancer

Drugs for Ovarian Epithelial Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 452)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
2
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 216974-75-3
3
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
4
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 33069-62-4 36314
5
Olaparib Approved Phase 4,Phase 3,Phase 2,Phase 1 763113-22-0 23725625
6
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1 31703
7 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
8 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
9 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
10 Albumin-Bound Paclitaxel Phase 4,Phase 3,Phase 2,Phase 1
11 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
12 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 2,Phase 1
13 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1
14 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1
15 Pharmaceutical Solutions Phase 4,Phase 2,Phase 1
16 Poly(ADP-ribose) Polymerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
17
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
18
Cyclophosphamide Approved, Investigational Phase 3,Phase 1,Phase 2 50-18-0, 6055-19-2 2907
19
Ifosfamide Approved Phase 2, Phase 3, Phase 1 3778-73-2 3690
20
Mechlorethamine Approved Phase 2, Phase 3, Phase 1 51-75-2 4033
21
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
22
Tamoxifen Approved Phase 3,Phase 2,Phase 1 10540-29-1 2733526
23
Topotecan Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 119413-54-6, 123948-87-8 60700
24
Lenograstim Approved Phase 3,Phase 1,Phase 2 135968-09-1
25
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
26
Pancrelipase Approved Phase 3,Phase 1,Phase 2 53608-75-6
27
Oxaliplatin Approved, Investigational Phase 3,Phase 1,Phase 2 61825-94-3 5310940 9887054 43805 6857599
28
Melphalan Approved Phase 3,Phase 2,Phase 1 148-82-3 4053 460612
29
Amifostine Approved, Investigational Phase 3,Phase 1,Phase 2 20537-88-6 2141
30
Pertuzumab Approved Phase 3,Phase 2 145040-37-5, 380610-27-5 2540
31
Epirubicin Approved Phase 3,Phase 2 56420-45-2 41867
32
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
33
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
34
Caspofungin Approved Phase 3,Phase 2 179463-17-3, 162808-62-0 468682 2826718
35
Palivizumab Approved, Investigational Phase 3 188039-54-5
36
Ribavirin Approved Phase 3 36791-04-5 37542
37
Fluconazole Approved Phase 3 86386-73-4 3365
38
Itraconazole Approved, Investigational Phase 3,Phase 1,Phase 2 84625-61-6 55283
39
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
40
Ondansetron Approved Phase 3,Phase 2 99614-02-5 4595
41
Captopril Approved Phase 3 62571-86-2 44093
42
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
43
Morphine Approved, Investigational Phase 3 57-27-2 5288826
44
Rucaparib Approved, Investigational Phase 3,Phase 2 283173-50-2 9931954
45
Trabectedin Approved, Investigational Phase 3,Phase 2,Phase 1 114899-77-3 108150
46
Capecitabine Approved, Investigational Phase 3,Phase 2,Phase 1 154361-50-9 60953
47
Mitoxantrone Approved, Investigational Phase 3,Phase 2,Phase 1 65271-80-9 4212
48
Estradiol Approved, Investigational, Vet_approved Phase 3,Phase 2 50-28-2 5757
49
Acetylcarnitine Approved, Investigational Phase 3,Phase 2 3040-38-8 1
50
Letrozole Approved, Investigational Phase 2, Phase 3 112809-51-5 3902

Interventional clinical trials:

(show top 50) (show all 1006)

id Name Status NCT ID Phase Drugs
1 A Study to Evaluate Efficacy and Tolerance of Caelyx in Patients With Epithelial Ovarian Cancer. (Study P04072)(COMPLETED) Completed NCT00727961 Phase 4 Pegylated Liposomal Doxorubicin hydrochloride
2 To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer Recruiting NCT02476968 Phase 4 Olaparib
3 Study of Clinical and Biological Prognostic Factors in Patients With Ovarian Cancer Receiving Carboplatin +Paclitaxel With Bevacizumab Active, not recruiting NCT01706120 Phase 4 Bevacizumab;Paclitaxel;Carboplatin
4 Magnetic Resonance Imaging for Lymph Node Staging in Ovarian Cancer Withdrawn NCT02243059 Phase 4 Gadofosveset trisodium (Ablavar™ )
5 Adjuvant Chemotherapy Compared With Observation in Treating Patients With Resected Early Stage Ovarian Epithelial Cancer Unknown status NCT00002477 Phase 3 carboplatin;cisplatin;cyclophosphamide;doxorubicin hydrochloride
6 Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer (EOC): A Phase III Randomized Study Unknown status NCT00715286 Phase 3
7 Monoclonal Antibody Therapy in Treating Patients With Ovarian Cancer or Primary Peritoneal Cancer in Remission Following Surgery and Chemotherapy Unknown status NCT00004115 Phase 3
8 Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Unknown status NCT00045461 Phase 2, Phase 3 carboplatin;ifosfamide
9 Trial of Tri-weekly TJ Versus Weekly TJ for Stage II-IV Mullerian Carcinoma Unknown status NCT00226915 Phase 3 Paclitaxel+Carboplatin;Paclitaxel+Carboplatin
10 Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer Unknown status NCT01087268 Phase 3
11 ICON8: Weekly Chemotherapy in Ovarian Cancer Unknown status NCT01654146 Phase 3 Carboplatin;Carboplatin;Paclitaxel;Paclitaxel
12 An RCT of Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer Unknown status NCT00532194 Phase 3 cediranib
13 Carboplatin With or Without Gemcitabine in Treating Patients With Advanced Ovarian Epithelial Cancer That Has Not Responded to Previous Chemotherapy Completed NCT00006453 Phase 3 carboplatin;gemcitabine hydrochloride
14 Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT00041080 Phase 3 tamoxifen citrate;thalidomide
15 Paclitaxel Plus Carboplatin With or Without Topotecan in Treating Patients With Stage IIB, Stage III, or Stage IV Ovarian Epithelial Cancer Completed NCT00006454 Phase 3 carboplatin;paclitaxel;topotecan hydrochloride
16 Carboplatin Plus Paclitaxel or Docetaxel in Treating Patients With Ovarian Epithelial Cancer Completed NCT00003998 Phase 3 carboplatin;docetaxel;paclitaxel
17 Comparison of Combination Chemotherapy Regimens in Treating Newly Diagnosed Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Completed NCT00028743 Phase 3 carboplatin;cisplatin;paclitaxel;topotecan hydrochloride
18 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Completed NCT00483782 Phase 3 carboplatin;paclitaxel
19 High-Dose Chemotherapy Compared With Standard Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer That Has Been Removed During Surgery Completed NCT00004921 Phase 3 carboplatin;cyclophosphamide;melphalan;paclitaxel
20 Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer Completed NCT00002568 Phase 3 cisplatin;paclitaxel
21 Early Post-Operative Enteral Feeding in Patients With Advanced Epithelial Ovarian Cancer Completed NCT00850772 Phase 3
22 Amifostine in Treating Patients With Ovarian Epithelial Cancer Who Are Receiving Chemotherapy Completed NCT00004166 Phase 3 amifostine trihydrate
23 Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer Completed NCT00003322 Phase 3 cisplatin;paclitaxel
24 Karenitecin Versus Topotecan in Patients With Advanced Epithelial Ovarian Cancer Completed NCT00477282 Phase 3 Karenitecin;Topotecan
25 Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer Completed NCT00011986 Phase 3 Paclitaxel;Carboplatin;Gemcitabine Hydrochloride;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
26 Caelyx Plus Carboplatin Versus Paclitaxel Plus Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse Completed NCT00189553 Phase 3 Pegylated liposomal doxorubicin;Carboplatin;Paclitaxel
27 Pertuzumab in Platinum-Resistant Low Human Epidermal Growth Factor Receptor 3 (HER3) Messenger Ribonucleic Acid (mRNA) Epithelial Ovarian Cancer (PENELOPE) Completed NCT01684878 Phase 3 Gemcitabine (Chemotherapy);Paclitaxel (Chemotherapy);Pertuzumab;Placebo;Topotecan (Chemotherapy)
28 Chemotherapy With or Without Surgery in Treating Patients With Stage II or Stage III Ovarian Cancer Completed NCT00003695 Phase 3 chemotherapy
29 Chemosensitivity Testing to Assign Treatment for Patients With Stage III or Stage IV Ovarian Cancer Completed NCT00003214 Phase 3 carboplatin;cisplatin;cyclophosphamide;doxorubicin hydrochloride;in vitro sensitivity-directed chemotherapy;paclitaxel
30 Platinum-based Chemotherapy With or Without Paclitaxel in Treating Patients With Relapsed Ovarian Cancer Completed NCT00002894 Phase 3 carboplatin;cisplatin;paclitaxel
31 OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer Completed NCT00382811 Phase 3 phenoxodiol;carboplatin;placebo
32 Carboplatin/Paclitaxel +/-Gemcitabine in Treating Patients With Ovarian Epithelial or Fallopian Tube Cancer Completed NCT00052468 Phase 3 TCG;TC
33 Chemotherapy Plus Surgery in Treating Patients With Stage III or Stage IV Ovarian, Peritoneal, or Fallopian Tube Cancer Completed NCT00003636 Phase 3 carboplatin;cisplatin
34 Gemcitabine Plus Carboplatin Versus Carboplatin Monotherapy in Patients With Advanced Ovarian Cancer Completed NCT00102414 Phase 3 Gemcitabine
35 A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer Completed NCT01239732 Phase 3 Paclitaxel;Bevacizumab;Carboplatin
36 Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer Completed NCT00002717 Phase 3 cisplatin;paclitaxel
37 Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer Completed NCT00003644 Phase 3 carboplatin;paclitaxel
38 TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Doxil in Platinum Refractory or Resistant Ovarian Cancer Completed NCT00102973 Phase 3 TLK286 in Combination with Carboplatin;Doxorubicin HCl Liposome Injection
39 Paclitaxel, Carboplatin, and Topotecan in Patients With Ovarian Cancer Completed NCT00102375 Phase 3 Topotecan
40 Secondary Debulking Surgery +/- Hyperthermic Intraperitoneal Chemotherapy in Stage III Ovarian Cancer Completed NCT00426257 Phase 3
41 Early Chemotherapy Based on CA 125 Level Alone Compared With Delayed Chemotherapy in Treating Patients With Recurrent Ovarian Epithelial , Fallopian Tube, or Primary Peritoneal Cancer Completed NCT00002895 Phase 3 chemotherapy
42 S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer Completed NCT00043082 Phase 3 carboplatin;pegylated liposomal doxorubicin hydrochloride
43 Paclitaxel and Carboplatin With or Without Epirubicin in Treating Patients With Stage IIB, Stage III, or Stage IV Invasive Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Completed NCT00004934 Phase 3 carboplatin;epirubicin hydrochloride;paclitaxel
44 Study of Paclitaxel in Patients With Ovarian Cancer Completed NCT00989131 Phase 3 Paclical®;Taxol®
45 TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer Completed NCT01204749 Phase 3 AMG 386;AMG 386 Placebo;Paclitaxel;Paclitaxel
46 Erlotinib or Observation in Treating Patients Who Have Undergone First-Line Chemotherapy for Ovarian Cancer, Peritoneal Cancer, or Fallopian Tube Cancer Completed NCT00263822 Phase 3 erlotinib hydrochloride
47 Timing of Surgery and Chemotherapy in Treating Patients With Newly Diagnosed Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer Completed NCT00075712 Phase 2, Phase 3 carboplatin;paclitaxel
48 S9701 Paclitaxel in Treating Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission Completed NCT00003120 Phase 3 paclitaxel
49 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
50 Carboplatin in Treating Patients With Stage IC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT00098878 Phase 3 carboplatin

Search NIH Clinical Center for Ovarian Epithelial Cancer

Genetic Tests for Ovarian Epithelial Cancer

Genetic tests related to Ovarian Epithelial Cancer:

id Genetic test Affiliating Genes
1 Ovarian Epithelial Cancer 29

Anatomical Context for Ovarian Epithelial Cancer

MalaCards organs/tissues related to Ovarian Epithelial Cancer:

39
Bone, Lung, Ovary, T Cells, Bone Marrow, Liver, Testes

Publications for Ovarian Epithelial Cancer

Articles related to Ovarian Epithelial Cancer:

(show top 50) (show all 82)
id Title Authors Year
1
Expression of inflammatory cytokines in ovarian epithelial cancer and their correlation. ( 28685546 )
2017
2
Detection of OPCML methylation, a possible epigenetic marker, from free serum circulating DNA to improve the diagnosis of early-stage ovarian epithelial cancer. ( 28693156 )
2017
3
Laparoscopic fertility-sparing surgery for early ovarian epithelial cancer: A multi-institutional experience. ( 27017986 )
2016
4
Overexpression of Notch3 and pS6 Is Associated with Poor Prognosis in Human Ovarian Epithelial Cancer. ( 27445438 )
2016
5
Desmocollin 3 mediates follicle stimulating hormone-induced ovarian epithelial cancer cell proliferation by activating the EGFR/Akt signaling pathway. ( 26261554 )
2015
6
Intraperitoneal administration of cisplatin plus bevacizumab for the management of malignant ascites in ovarian epithelial cancer: results of a phase III clinical trial. ( 25609006 )
2015
7
Prognostic Factors for Ovarian Epithelial Cancer in the Elderly: A Case-Control Study. ( 25768081 )
2015
8
Heterogeneity of tumor chemosensitivity in ovarian epithelial cancer revealed using the adenosine triphosphate-tumor chemosensitivity assay. ( 26137074 )
2015
9
Nedd4L expression is decreased in ovarian epithelial cancer tissues compared to ovarian non-cancer tissue. ( 26554540 )
2015
10
Lysophosphatidic Acid Stimulates Urokinase Receptor (uPAR/CD87) in Ovarian Epithelial Cancer Cells. ( 26408685 )
2015
11
Overexpression of Class III I^-tubulin, Sox2, and nuclear Survivin is predictive of taxane resistance in patients with stage III ovarian epithelial cancer. ( 26198101 )
2015
12
Ovarian sarcoma carries a poorer prognosis than ovarian epithelial cancer throughout all FIGO stages: a single-center case-control matched study. ( 25503164 )
2014
13
Inhibitory role of prohibitin in human ovarian epithelial cancer. ( 24966933 )
2014
14
The microRNA-27a: ZBTB10-specificity protein pathway is involved in follicle stimulating hormone-induced VEGF, Cox2 and survivin expression in ovarian epithelial cancer cells. ( 23254909 )
2013
15
Chemoresistance is associated with MUC1 and Lewis y antigen expression in ovarian epithelial cancers. ( 23708102 )
2013
16
Expression of steroid receptor coactivator 3 in ovarian epithelial cancer is a poor prognostic factor and a marker for platinum resistance. ( 23652306 )
2013
17
Cytologic changes of ovarian epithelial cancer induced by neoadjuvant chemotherapy. ( 24133590 )
2013
18
Over-expression of semaphorin4D, hypoxia-inducible factor-1I+ and vascular endothelial growth factor is related to poor prognosis in ovarian epithelial cancer. ( 23202951 )
2012
19
Primary human ovarian epithelial cancer cells broadly express HER2 at immunologically-detectable levels. ( 23189165 )
2012
20
Expression and significance of the TLR4/MyD88 signaling pathway in ovarian epithelial cancers. ( 22985132 )
2012
21
Fibrillar type I collagen matrices enhance metastasis/invasion of ovarian epithelial cancer via I^1 integrin and PTEN signals. ( 23013730 )
2012
22
Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. ( 22895947 )
2012
23
Novel approaches to quantify estradiol-induced loss of ERI^1 protein in older mouse ovarian surface epithelium: new tools to assess the role of ER protein subtypes in predisposing to ovarian epithelial cancer? ( 21773845 )
2011
24
Ovarian epithelial cancer stem cells. ( 21666993 )
2011
25
Target genes suitable for silencing approaches and protein product interference in ovarian epithelial cancer. ( 19945796 )
2010
26
[Effects of PTEN over-expression on phosphatidyl inositol 3-kinase/protein kinase B signal pathway in ovarian epithelial cancer cells]. ( 21092549 )
2010
27
High-throughput DNA hypermethylation profiling in different ovarian epithelial cancer subtypes using universal bead array. ( 20811671 )
2010
28
Immunohistochemical expression of epidermal growth factor receptor, E-cadherin, and matrix metalloproteinase-9 in ovarian epithelial cancer and relation to patient deaths. ( 21074685 )
2010
29
A useful cell system for studying the regulation of 17HSD/KSR type 2 activity and expression in ovarian epithelial cancer. ( 20600897 )
2010
30
Overexpression of follicle-stimulating hormone receptor facilitates the development of ovarian epithelial cancer. ( 19181441 )
2009
31
Oxidation of ovarian epithelial cancer cells by hypochlorous acid enhances immunogenicity and stimulates T cells that recognize autologous primary tumor. ( 18676764 )
2008
32
Multitargeting ovarian epithelial cancer: adding the old to the new. ( 18349413 )
2008
33
[Analysis of serum biomarkers of ovarian epithelial cancers based on 2-DE DIGE and MALDI TOF/TOF]. ( 19173805 )
2008
34
Keratinocyte chemoattractant (KC)/human growth-regulated oncogene (GRO) chemokines and pro-inflammatory chemokine networks in mouse and human ovarian epithelial cancer cells. ( 17712227 )
2007
35
Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. ( 17943850 )
2007
36
[Screening and sero-immunoscreening of ovarian epithelial cancer associative antigens]. ( 18476518 )
2007
37
Two-tier grading system for ovarian epithelial cancer: has its time arrived? ( 17667555 )
2007
38
Differential role of gonadotropin-releasing hormone on human ovarian epithelial cancer cell invasion. ( 17906381 )
2007
39
[Expression of phosphorylated protein kinase B and PTEN protein in ovarian epithelial cancer]. ( 17673045 )
2007
40
Analysis of the expression of estrogen receptor, progesterone receptor and chicken ovalbumin upstream promoter-transcription factor I in ovarian epithelial cancers and normal ovaries. ( 17549341 )
2007
41
Raised serum chondroitin sulfate epitope level in ovarian epithelial cancer. ( 16936295 )
2006
42
Debulking surgery for ovarian epithelial cancer performed by a gynaecological oncologist improved survival compared with less specialised surgeons. ( 16707225 )
2006
43
Ovarian epithelial cancer: a role for PGE2-synthesis and signalling in malignant transformation and progression. ( 17107625 )
2006
44
Expression of MTA2 gene in ovarian epithelial cancer and its clinical implication. ( 16961294 )
2006
45
Induction of apoptosis in human ovarian epithelial cancer cells by antisurvivin oligonucleotides. ( 15944801 )
2005
46
Cyclooxygenase-1 is a potential target for prevention and treatment of ovarian epithelial cancer. ( 15867369 )
2005
47
Aromatase expression in ovarian epithelial cancers. ( 15748828 )
2005
48
Lack of relationship between EGFR-1 immunohistochemical expression and prognosis in a multicentre clinical trial of 93 patients with advanced primary ovarian epithelial cancer (GINECO group). ( 15226774 )
2004
49
First-line intraperitoneal cisplatin-paclitaxel and intravenous ifosfamide in Stage IIIc ovarian epithelial cancer. ( 15171311 )
2004
50
Borderline ovarian epithelial cancer. ( 21213507 )
2004

Variations for Ovarian Epithelial Cancer

ClinVar genetic disease variations for Ovarian Epithelial Cancer:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
2 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
3 PIK3CA NM_006218.3(PIK3CA): c.1636C> A (p.Gln546Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh37 Chromosome 3, 178936094: 178936094

Expression for Ovarian Epithelial Cancer

Search GEO for disease gene expression data for Ovarian Epithelial Cancer.

Pathways for Ovarian Epithelial Cancer

Pathways related to Ovarian Epithelial Cancer according to GeneCards Suite gene sharing:

(show all 35)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.63 AKT2 COL1A1 MAPK1 PTGS2
2 12.46 AKT2 COL1A1 MAPK1 PTGS2
3 12.35 AKT2 BIRC5 MAPK1 PTGS2
4
Show member pathways
12.22 AKT2 MAPK1 PTGS2
5
Show member pathways
12.19 AKT2 BIRC5 MAPK1
6
Show member pathways
12.11 AKT2 MAPK1 PTGS2
7 12.07 AKT2 BIRC5 MAPK1 PTGS2
8
Show member pathways
12.04 AKT2 MAPK1 PHB
9
Show member pathways
12.03 AKT2 MAPK1 PTGS2
10
Show member pathways
11.98 AKT2 COL1A1 MAPK1
11
Show member pathways
11.95 AKT2 MAPK1 PTGS1 PTGS2
12 11.93 BIRC5 MAPK1 PTGS2
13 11.72 MAPK1 PTGS1 PTGS2
14 11.69 AKT2 MAPK1 PTGS2
15 11.6 AKT2 COL1A1 MAPK1
16 11.44 AKT2 BIRC5 MAPK1
18 11.37 BIRC5 PTGS2
19 11.37 COL1A1 PTGS1
20 11.34 MAPK1 PTGS2
21
Show member pathways
11.3 BIRC5 MAPK1 PTGS2
22 11.29 BIRC5 MAPK1
23 11.21 BIRC5 PTGS2
24 11.1 PTGS1 PTGS2
25 11.06 PTGS1 PTGS2
26 11.06 AKT2 PTGS1 PTGS2
27
Show member pathways
11.04 PTGS1 PTGS2
28 11.01 AKT2 MAPK1
29 11.01 AKT2 COL1A1 MAPK1 PTGS1
30 10.97 PTGS1 PTGS2
31 10.94 PTGS1 PTGS2
32 10.93 COL1A1 MAPK1
33 10.8 PTGS1 PTGS2
34 10.73 AKT2 BIRC5 MAPK1
35 10.69 PTGS1 PTGS2

GO Terms for Ovarian Epithelial Cancer

Cellular components related to Ovarian Epithelial Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 early endosome GO:0005769 8.8 AKT2 MAPK1 PHB

Biological processes related to Ovarian Epithelial Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 positive regulation of cell migration GO:0030335 9.5 AKT2 COL1A1 MAPK1
2 positive regulation of cell death GO:0010942 9.37 PHB PTGS2
3 positive regulation of cell proliferation GO:0008284 9.33 BIRC5 MAPK1 PTGS2
4 prostaglandin metabolic process GO:0006693 9.26 PTGS1 PTGS2
5 prostaglandin biosynthetic process GO:0001516 8.96 PTGS1 PTGS2
6 cyclooxygenase pathway GO:0019371 8.62 PTGS1 PTGS2

Molecular functions related to Ovarian Epithelial Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 peroxidase activity GO:0004601 8.96 PTGS1 PTGS2
2 prostaglandin-endoperoxide synthase activity GO:0004666 8.62 PTGS1 PTGS2

Sources for Ovarian Epithelial Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....